Home

  • Who are we?

    A Biotech Venture Capital Leader

    Based in Montreal, CTI Life Sciences Fund L.P. is a limited partnership formed in 2006. The Fund makes venture capital investments in high quality emerging life sciences companies at the pre-clinical and clinical development stage primarily in Canada. The Fund is the first of its kind created in Quebec since 2002. We are currently working on a second biotech Fund of C$150 million that should open in the course of 2014.

  • Our first fund is

    A Success In the Industry

    CTI Life Sciences Fund L.P. has secured C$100 million in commitments from Quebec, institutional investors such as the Caisse de dépôt et placement du Québec, the Solidarity Fund QFL, FIER Partners L.P. and the Régime de rentes du Mouvement Desjardins and CTI Capital Group’s partners.

  • Our latest exit:

    Medicago for C$357M

    Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announced today that it has entered into a definitive arrangement agreement with Mitsubishi Tanabe Pharma Corporation.

    Read More

Geography

We are actively seeking to invest our Fund 1/3 in the province of Quebec, 1/3 in the rest of Canada and 1/3 Internationally in high promising biotech companies

Targeted Investments

We invest in pre-clinical to Phase III biotechs. Our position range from simple to lead investor. Sometimes, we take an active role in the decision making process

First Quartile Performance

So far, we have exited three of our positions and still have many promising ventures in the pipeline. Our largest success was the sale of Enobia Pharma to Alexion for $1.1B

Team Overview

One of the key differentiators of the Fund’s unique capability in the investment process is the quality of its management whose members bring their considerable and diverse knowledge of value creation as well as the elements which result in successful exits in biotech and the technologies markets.